Drug Approval | December 20, 2025
GSK’s Exdensur gains FDA nod for severe asthma with just two doses a year
The approval for Exdensur (depemokimab-ulaa) comes on the back of SWIFT-1 and SWIFT-2 Phase III trials
The approval for Exdensur (depemokimab-ulaa) comes on the back of SWIFT-1 and SWIFT-2 Phase III trials
The center will deliver Certified Pre-Owned instruments restored to factory-grade standards and backed by Agilent Standard Warranty
The move strengthens GBL’s clinical-stage presence in the United States
The reform is set to modernise how medicines are developed, authorised, and made available across the EU
Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
The approval of Augmentin XR, granted to USAntibiotics, directly supports the CNPV program’s goals
Roche says its new assay “resolves this challenge by delivering accurate and specific results
The agreement pairs Croda’s global footprint and “smart science” approach with Amino’s precision manufacturing capabilities
It's a development that marks a potential breakthrough for people living with the rare and debilitating disease Duchenne muscular dystrophy (DMD)
Captured microbes are then neutralized on engineered microbicidal surfaces
Subscribe To Our Newsletter & Stay Updated
